WILMINGTON, MA--(Marketwire - March 06, 2009) - DUSA Pharmaceuticals, Inc. (NASDAQ: DUSA) announces that its corporate highlights and year end financial results press release will be issued on Wednesday, March 11th at 6:30 a.m. to be followed by a conference call at 8:30 a.m.
Wednesday, March 11 - 8:30 a.m. E.T.
If calling from the US or Canada use the following toll-free number:
800.647.4314
Password - DUSA
For International callers use
502-498-8422
A recorded replay of the call will be available approximately
15 minutes following the call
North American callers 877.863.0350
International callers 858.244.1268
The call will be accessible on our web site approximately four hours following the call at www.dusapharma.com.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical
company focused primarily on the development and marketing of its
Levulan® photodynamic therapy (PDT) technology platform, and
complementary dermatology products. Levulan PDT is currently approved for
the treatment of Grade 1 or 2 actinic keratoses of the face or scalp. DUSA
is also researching additional indications for Levulan PDT, including oral
leukoplakia in collaboration with the National Institutes of Health (NIH)
and the prevention of AKs and SCCs in immunosuppressed solid organ
transplant recipients. DUSA is based in Wilmington, Massachusetts. Please
visit the company's Web site at www.dusapharma.com for more information.
